2Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a muhidrug regimen in the developing world: a cost-effectiveness analysis[J]. Lancet, 2006,19,368(9536) :679
3Lanza CA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing[ J ]. Adv Cardiol,2006,43:1
4Siddiqui A, Kowey PR. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies[ J]. Curr Opin Cardiol,2006,21(5) :517
5Viitasalo M, Oikarinen L, Swan H, et al. Effects of beta-blocker therapy on ventricular repolarization documented by 24 h electrocardiography in patients with type 1 long-QT syndrome[J]. J Am Coll Cardiol,2006,48 (4) :747
6Pedersen ME, Cockcroft JR. The latest generation of beta-blockers :new pharmacologic properties [ J ]. Curr Hypertens Rep, 2006, 8(4):279
7Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines[J]. Eur Heart J, 2006,27(16) :1 979
8Zipes DP, Carom AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sadden cardiac death-executive summary : a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines [ J ]. Eur Heart J, 2006,27 ( 17 ) :2 099
9Blomstrom C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC Guidelines for the management of patients with supraventricular arrhythmias [ J ]. J Am Coll Cardiol,2003,42 ( 8 ) : 1493
10Adamson PB, Gilbert EM. Reducing the risk of sudden death in heart failure with beta-blockers[J]. J Card Fail,2006,12(9) :734
4Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decom- pensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical tri- al[J]. JAm Coll Cardiol, 2007,50( 19).: 1 835.
5Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: exec- utive summary (update 2005) :The Task Force for the Di- agnosis and Treatment of Chronic Heart Failure of the Eu- ropean Society of Cardiology[J]. Eur Hea't J, 2005, 26 (11):1 115.
6George I, Morrow B, Xu K, et al. Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury[J]. Am J Physiol Heart Circ Physiol, 2009,297 (2) : H708.
7Publication Committee for the VMAC Investigators (Va- sodilatation in the Management of Acute CHF). Intrave- nous nesiritide vs nitroglycerin for treatment of decompen- sated congestive heart failure : a randomized controlled tri- al[J]. JAMA, 2002,287(12) : 1 531.
8Dandamudi S, Chen HH. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompen- sated heart failure[J]. Expert Rev Cardiovasc Ther, 2012, 10(5):557.
9Wang D J, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function inpatients with chronic heart failure and worsening scram crcatinine[J]. Circulau- on, 2004,110(12):i 620.
10Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial[J]. JAM_A, 2005,294(13) : 1 625.
